Cerebrolysin (60 mg vial)

Protocol Overview

Concise summary of the regimen.

Dosing & Reconstitution

Frequency: Inject once or twice daily subcutaneously. Doses exceeding 100 units (1.0 mL) should be split into AM and PM administrations. Clinical literature describes daily doses ranging from 215 mg (1 mL of commercial solution) up to higher IV infusions; this protocol uses a conservative subcutaneous approach with gradual titration.

Reconstitution Steps

1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid foaming.
3. Gently swirl until dissolved (do not shake).
4. Label and refrigerate at 2 to 8 °C, protected from light; use within 7 days. At 20 mg/mL, 1 unit = 0.01 mL = 200 mcg (0.2 mg) on a U-100 insulin syringe.

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: store at controlled room temperature at or below 25 °C in dry, dark conditions; do not freeze.
• Reconstituted: refrigerate at 2 to 8 °C; use within 7 days; protect from light.
• Allow vials to reach room temperature before opening to reduce condensation uptake.

Supplies Needed

Plan based on an 8 to 16 week daily protocol with gradual titration.

Peptide Vials (Cerebrolysin, 60 mg each):

• 8 weeks: ~26 vials. 12 weeks: ~42 vials. 16 weeks: ~58 vials.

Insulin Syringes (U-100):

• Week 1 (1/day): 7. Weeks 2 to 16 (2/day): split.
• 8 weeks total: 105. 12 weeks: 161. 16 weeks: 217.

Bacteriostatic Water (10 mL bottles):

• 8 weeks (26 vials): 8 bottles. 12 weeks (42 vials): 13 bottles. 16 weeks (58 vials): 18 bottles.

Alcohol Swabs:

• 8 weeks: 210 (3 x 100-count). 16 weeks: 434 (5 x 100-count).

Important Notes

Practical considerations for consistency and safety.

• Use new sterile insulin syringes; dispose in a sharps container.
• Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
• Inject slowly; wait a few seconds before withdrawing the needle.
• Document daily dose, timing (AM/PM), and site rotation to maintain consistency.
• For doses exceeding 100 units (1.0 mL), split into two separate injections at different sites.

How This Works

Cerebrolysin is a multicomponent peptide preparation derived from porcine brain tissue, containing biologically active neuropeptides and amino acids with molecular weights below 10 kDa. This low molecular weight allows it to cross the blood-brain barrier and exert neurotrophic effects similar to endogenous factors like nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF). Preclinical studies demonstrate neuroprotective effects including reduced infarct size and improved recovery in ischemia models. Human trials have examined its use in stroke, dementia, and traumatic brain injury with mixed but generally favorable tolerability profiles.

Benefits & Side Effects

Observations from preclinical and clinical literature.

• Preclinical models consistently show neuroprotective effects including reduced neuronal damage and

improved functional recovery after ischemic insult.

• Meta-analyses of human dementia trials suggest modest cognitive benefits with daily IV infusions; stroke

trial results have been more variable.

• Generally well tolerated in short-term use; occasional mild injection-site reactions may occur with

subcutaneous administration.

• Rare reports of dizziness, headache, or gastrointestinal upset; discontinue and consult a professional if

significant adverse effects occur.

Lifestyle Factors

Complementary strategies for best outcomes.

• Maintain a nutrient-dense diet rich in omega-3 fatty acids, antioxidants, and B-vitamins.
• Engage in regular aerobic exercise and cognitive stimulation to reinforce neuroplasticity.
• Prioritize quality sleep (7 to 9 hours) and stress management to optimize recovery and brain function.
• Avoid excessive alcohol and other neurotoxic substances during the protocol.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and skin with alcohol; allow to dry.
2. Pinch a 2 to 4 cm skinfold; insert the needle at 45 to 90 degrees into subcutaneous tissue.
3. Do not aspirate for subcutaneous injections; inject slowly and steadily.
4. Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.
5. For split-dose protocols (AM/PM), use different injection sites for each administration.

References

Source citations for further reading.

1. Meta-analysis of Cerebrolysin efficacy in acute ischemic stroke (Med Sci Monit, 2017).
2. Neuroprotective action of Cerebrolysin in acute/chronic brain ischemia (PLOS One, 2021).